Total Artificial Heart

dc.contributor.author	Elsaeiti, Sajedah
dc.contributor.author	Hamouda, Yomna
dc.contributor.author	Eloriby, Doaa
dc.contributor.author	Elmesmari, Shahed
dc.date.accessioned	2021-02-28T11:19:52Z
dc.date.available	2021-02-28T11:19:52Z
dc.date.issued	2021-02-28
dc.identifier.uri	http://repository.limu.edu.ly/handle/123456789/2788
dc.description	Heart transplantation remains the gold standard treatment for endstage heart failure. The Total Artificial Heart (TAH) is the only Food and Drug Administration (FDA) approved artificial heart used for bridging patients to transplantation. Outcomes in patients who undergo implantation of the TAH at experienced centers have been good and reproducible.	en_US
dc.language.iso	en	en_US
dc.publisher	Faculty of Pharmacy	en_US
dc.rights	Attribution 3.0 United States	*
dc.rights.uri	http://creativecommons.org/licenses/by/3.0/us/	*
dc.title	Total Artificial Heart	en_US
dc.type	Presentation	en_US

Except where otherwise noted, this item's license is described as Attribution 3.0 United States